General MedicationsORALStandard
LIVDELZI
SELADELPAR LYSINE
Standard Dose
EQ 10MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LIVDELZI is listed in Drugs@FDA under application 217899 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient SELADELPAR LYSINE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2026-01-30 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIVDELZI is listed in Drugs@FDA under application 217899 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SELADELPAR LYSINE Form and strength CAPSULE;ORAL - EQ 10MG BASE Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2026-01-30 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.